Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION The working file is complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week. Clinical-development physician in a biologics company planning a biosimilar pathway has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. The population in complete-response-letter deficiency list is the one an inspector asking for batch records you cannot produce this week named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in complete-response-letter deficiency list is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the pathway is the honest Pharma & Life Sciences call. 3. A biologics company planning a biosimilar pathway already contained an inspector asking for batch records you cannot produce this week before complete-response-letter deficiency list arrived; no new Clinical and Evidence Strategy path. 4. Provenance on complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 3. Check whether complete-response-letter deficiency list supports the labeled claim clinical-development physician would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read complete-response-letter deficiency list against an inspector asking for batch records you cannot produce this week and write the one fact that would move the 505(b)(2) bridge is for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for clinical-development physician in a biologics company planning a biosimilar pathway.